Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine in Schizophrenia
NCT07145918Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emraclidine in schizophrenia (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 74 days, Maximum Observed Plasma Concentration of Emraclidine at 24 days and 22 more. Started Aug 2025; status: recruiting.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07145918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145918.